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Abstract
Asthma in Scotland: prescribing trends since the National Review of Asthma Deaths
(NRAD)
Purpose: Asthma remains prevalent worldwide with implications for morbidity and
mortality. In Scotland, 1 in 14 people are currently being treated for asthma. Asthma burden
prompted the creation of the National Review of Asthma Deaths (NRAD), which identified
contributing factors. Since the NRAD, guidelines have changed and therapeutic indicators
have been developed with an increased emphasis on controller medications. Few
publications describe how the NRAD study affected prescribing and if inequalities among
the asthmatic population exist. This study aimed to determine whether patients were
receiving appropriate treatment according to therapeutic guidelines and how prescribing
has changed over time.
Methods: Scotland’s Prescribing Information System (PIS) was used to gain access to
population-based outpatient prescription drug claims for Short-Acting Beta-Agonists
(SABAs), Long-Acting Beta-Agonists (LABAs), and Inhaled Corticosteroids (ICSs), to
create a cohort of asthma patients aged 0-39. All ethical approvals necessary were obtained
according to the National Health System (NHS) of Scotland’s specified guidelines for deidentified patient data. Patients were stratified by age, gender, socioeconomic status (SES),
and medication type to compare rates of prescribing for different populations. Using
NRAD and the national therapeutic indicators as metrics, the data was analyzed to assess
changes over time. The primary outcomes included whether there was a difference in
asthma prescribing from 2014 to 2018; if there were any significant demographics
differences among those with uncontrolled asthma; and whether drug claims were
consistent with asthma guidelines.
Results: A total of 222,637 patients were analyzed from 2014 and 205,758 from 2018. In
2018, 7.42% of those received more than 12 SABAs per year, 20.77% received more than
6, and 42.39% received more than 3, only slightly lower than in 2014 (8.85%, 21.83%,
43.73% respectively). For the most recent year that data was available (2018) further
analyses were completed. Prevalence of receiving more than 12 SABAs was found to be
higher among patients who were male, as well as patients aged 30-39, or those with lower
SES. Use of greater than 12 SABAs varied almost two-fold between the populations with
the highest and lowest SES (lowest SES – 9.0%; highest SES – 4.6%). When looking at
measures related to the therapeutic guidelines, only 89% of patients receiving more than
12 SABAs had received an ICS; of those, only 41% received an adequate amount of ICS
medications over the year.
Conclusion: Prescribing practices have changed slowly since the NRAD study was
published. When looking at the therapeutic guidelines, prescription drug claims show a
disconnect with the recommendations. There appears to remain an over-reliance on reliever
medications with a deficit in controller medications. This study shows that a large Scottish
asthmatic population remains at increased risk of poor outcomes. More studies are needed
to further research hospitalization, morbidity, and mortality rates as well as cost analyses,
to further characterize change over time and whether new measures are needed to improve
outcomes.
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Introduction
Asthma is a chronic inflammatory disease of the respiratory system that can result
in dyspnea, wheezing, cough, and chest tightness due to airway obstruction [1]. The
underlying pathophysiology and resulting airway obstruction can lead to potentially severe
respiratory symptoms, limitations of activity, and asthma attacks (exacerbations) that can
require urgent healthcare attention and can even be fatal [2]. Poorly controlled asthma has
been linked to increases in the risk of poor quality of life, increased asthma attacks,
increased healthcare expenditures, and even premature death [3,4].
Asthma remains a prevalent issue worldwide, with approximately 300 million
people estimated to have asthma and an estimated 100 million more to be affected by the
year 2025 [5,6]. While asthma-related hospitalizations and deaths have been shown to
decrease in most countries [7], the global burden for patients with exacerbations and dayto-day symptoms has increased by almost 30% in the past 20 years [8]. In addition, the
World Health Organization (WHO) has estimated that 15 million disability-adjusted life
years are lost, and 250,000 asthma deaths are reported annually worldwide [9]. In the
United Kingdom (UK), 5.4 million people are currently receiving treatment for asthma
[10]. More concerning is that the UK had a 20% increase in the rate of asthma attack deaths
over the five-year period from 2010 to 2015, culminating in 1434 people dying of an
asthma attack in 2015 [11]. This spike prompted the National Review of Asthma Deaths
(NRAD) in which the asthma deaths were reviewed to see if any common preventable
mistakes might have precipitated the deaths.
The factors the NRAD looked at included: the use of National Health System
(NHS) services, medical & professional care, prescribing & medicines use, patient factors,
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and perception of risk or poor control [12]. The findings of the prescribing and medicines
use component represents the basis for this study. Common asthma medications classes
include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and
inhaled corticosteroids (ICSs). These medication classes can be categorized into reliever
(SABAs and LABAs) or preventer medications (ICSs). Reliever medications only relieve
the symptoms through dilating the airways allowing more air to pass through. In contrast,
preventer medications help prevent the underlying cause of inflammation, allowing
reversal of the pathophysiological changes that occur due to asthma [13]. Among the
findings of NRAD in prescribing and medicines use was that there was evidence of
excessive prescribing of reliever medications (SABAs), under-prescribing of preventer
medications (ICSs), and evidence of inappropriate prescribing of LABA inhalers [12]. In
addition to this, the NRAD found that 65% of the asthma deaths reviewed had a preventable
factor [12]. These results showed that asthma treatment can be vastly improved in the UK
and that there remains a population at-risk for fatal consequences despite advances in
asthma treatment over the years.
In response to the NRAD, NHS Scotland issued National Therapeutic Indicators
(NTI) aimed at medication findings of the study. NTIs are used to alert healthcare
practitioners of a potential marker for poor disease state management that can be tracked
over time. These NTIs represent a way to use prescription data to inform and monitor
markers for potential poor economic outcomes, reduced healthcare outcomes, including
impacts of morbidity and mortality, as well to track prescribing patterns in various regions
of Scotland [14]. An example of an asthma NTI issued after the NRAD relevant to this
study is, “More than 12 SABAs per annum as a percentage of all people prescribed SABAs
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[15].” In addition to NTIs, disease-specific guidelines exist for numerous healthcare topics.
For asthma, the main guidelines of reference in Scotland are the Scottish Intercollegiate
Guideline Network/ British Thoracic Society (SIGN/BTS), but there also exists the
National Institute for Health and Care Excellence (NICE), and the Global Initiative for
Asthma (GINA). There is one specific change in the SIGN/BTS guidelines that is of
interest to this study. This change is the add on of ICS medications as first-line options in
the treatment of asthma. When the NRAD was published in 2014, the guidelines stated to
start SABA medication as first-line then if the asthma is not controlled add on ICS [Figure
1, appendix]. In 2016 an update was released, and the main treatment change was
considering add-on of ICS as soon as someone is diagnosed with asthma [Figure 2,
appendix]. This change could result in ICS medications being started earlier in the
treatment of asthma and could have implications on asthma outcomes.
When looking at the history of medication usage for asthma, there are many
instances of changes to prescribing guidelines as more information and new medications
are introduced. Medications have played a direct role in the decrease in mortality in the last
50 years but can also be linked to spikes in mortality during specific time frames [12,16,17].
These publications help to show the changes over time of asthma prescribing and give a
snapshot of the implications that asthma medications have on outcomes. The interplay of
evidence-based medicine and uptake into practice is a relevant interest for the data-driven
and connected world. It is suggested that it sometimes takes more than a decade to
implement research results in clinical practice and that it is often challenging to sustain
innovations over time [18]. With all of the available resources and guidelines specific to
asthma, it is understandably a daunting task for healthcare providers to remain up to date

8

with this complex disease that represents just one of the numerous chronic diseases. It is
of interest to understand and have methods to influence prescribing habits to coincide with
the most recent information.
Based upon the NRAD, Scotland’s NTIs, and changes in asthma guidelines, there
is a lot of evidence for how asthma should be treated and the implications on health for
asthma that is not managed adequately. While research forms the basis for these guidelines,
there are a multitude of other factors that can influence whether or not the health outcomes
reflect treatment under ideal situations. Some of these factors that affect asthma outcomes
include adherence, proper inhaler technique, prescribing that matches the latest guidelines,
and socioeconomic factors [19,20,21,22]. Few publications describe how the NRAD study
affected prescribing in Scotland and if inequalities exist in their asthmatic populations. This
study aimed to determine whether patients were receiving appropriate treatment according
to therapeutic guidelines and how asthma medication prescribing has changed over time.
NHS Scotland data was used to see the effects over time, utilizing the Prescribing
Information System (PIS) dataset. The objectives of this study include: determine if there
has been a change in asthma prescribing since the NRAD study was published using NRAD
and NTI measures; determine if there is a difference for asthma medication prescribing
among age, gender, and socioeconomic status; determine if the SIGN/BTS guidelines are
being followed in those receiving medications used to treat asthma.
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Methods

Scotland’s Prescribing Information System (PIS) was used as the data source for
this study. PIS is the definitive data source for prescribing information of all items
dispensed in the outpatient setting in Scotland. The data is maintained and used by the
Information Services Division (ISD) of the NHS National Services Scotland (NSS). The
data includes unique patient identifier (UPI), patient demographics, prescriber and
dispenser details, geographical and deprivation details, as well as costs and drug
information. The data have been collected since 1993 and gets updated monthly. The UPI
has been attached to the prescribing data since 2009 and allows for linking of prescription
events to an individual as well as linking of prescription events for a population based on
patient-specific information and demographics. The main limitation of PIS is that there are
no diagnosis codes attached to the dispensing information. As a result, assumptions were
made regarding indication, the severity of asthma, and adherence. The study population is
only those in Scotland that have gotten a SABA medication. Because SABAs can be used
for other ailments besides asthma, a quantity filter was added to help differentiate between
short-term SABA use for ailments like pneumonia and long-term SABA use for asthma.
The quantity filter stratified patients into those receiving greater than 3, 6, and 12 SABAs.
These quantity filters are not mutually exclusive; a patient receiving 13 SABAs in the year
would be included in patient counts of each SABA quantity category (>3, >6, and >12
SABAs). These quantity filters were selected because they have been used in previous
studies, including the NRAD [12]. There is also overlap with asthma and COPD. To
account for this age boundaries and age strata were also used to lessen the amount of COPD
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patients among the study population and to be able to see how SABA use changed with
age. COPD is a chronic disease that becomes apparent after 40 or 50 years of age [23].
Limiting the study population of asthma to patients aged 39 or younger allows less overlap
between asthma and COPD.
Another assumption that was made was the definition of uncontrolled asthma. For
this, it is assumed that patients in higher SABA quantity strata had asthma that was less
well-controlled than patients in the lower SABA quantity strata. In the context of outside
literature definition of asthma control, the SIGN/BTS guidelines have a practical definition.
It defines uncontrolled asthma in need of additional therapy as the use of 3 doses or more
of a SABA per week [24]. To put this into context, in 2018, the most dispensed SABA is
one that contains 200 doses per canister. This medication accounted for approximately 78%
of SABA dispensing. By the SIGN/BTS definition for uncontrolled asthma, this would
mean that if they had controlled asthma, then they would only be using a max of 2 doses
per week. With the most commonly dispensed inhaler, it would last them 100 weeks,
meaning they would only need one inhaler per year. While some circumstances can result
in an asthmatic needing inhalers on-hand in different locations that are not actively being
used, the quantity filters can help to gauge the control of a patient’s asthma. The last
assumption is that adherence is not a confounder for potential differences in the 2014 and
2018 data. It is assumed that adherence is constant between the years so that inferences can
be made about prescribing trends. This is further discussed in the discussion section and
represents an area to investigate in follow-up studies. The result of these assumptions can
over-estimate the asthmatic population, but the filters allow a more accurate representation
of those with asthma and allow a reference point to try and gauge poorly controlled asthma.
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When factoring in a comparison between two years, this can also allow for a good overview
of how asthma prescribing has changed.
Trial Design
The study was conducted as a cross-sectional study using PIS data in the years 2014
and 2018. The two years were used to assess changes over time in prescribing trends to see
the effect of guideline changes, NTI, and the NRAD. Then the year 2018 data was
expanded to look more in-depth at the demographics of the Scotland asthma population to
assess risk-factors for poorly controlled asthma in the most recent complete years data. The
program SAP BusinessObjects Business Intelligence 4.1 was used to retrieve data. This
program was used to query the data and pull data specific to set parameters. While the year
2018 was used because it was the most recent available, the year 2014 was used because
this was the year that the NRAD was published and the baseline/ reference population data
for the study. The data was retrieved on June and July 2019.
The queries were designed to make a study population that included all of those
that received a SABA medication as defined by the British National Formulary (BNF) in
2014 and 2018 that were aged 0-39. This population was then filtered using age strata (09, 10-19, 20-29, 30-39), approved drug name, drug formulation, paid calendar year, BNF
item description, medications by paid quantity (SABA, LABA, ICS, and combo inhalers),
Scottish Index of Multiple Deprivation (SIMD), and gender description in various
combinations to test the objectives. These filters were selected and used as categorical data
as opposed to continuous data to allow more insight into which part of the Scotland
population is most at-risk for poor outcomes. This choice was assumed to give more
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information that can be used for follow-up studies or interventions, than if continuous
variables were utilized.
For objective 1, the two years were compared to see how asthma prescribing has
changed over time. This compared the prescribing of SABA, LABA, and ICS between the
two years. Patient counts were conducted for the total number of patients that received a
SABA, patient count receiving >3, >6, and >12 SABAs; patient count of any ICS, ≥12 ICS,
and >14 ICS; patient count receiving any LABA, and LABA monotherapy. The patient
counts were then changed into percent, and rates, utilizing rate per 1000 patients. Relative
risk was then calculated between 2014 and 2018, with the year 2014 being used as a
baseline to see if there were changes over time. For objective 2, the data from 2018 was
filtered by age, gender, and socioeconomic status to look to see if there were any
demographic differences for those utilizing SABA inhalers or if there was a difference in
demographics for those with poorly controlled asthma. Rates were compared in the >3, >6,
and >12 SABA groups between age, gender, and SIMD. Relative risk was used to calculate
differences in the groups, with the entire population being used as the reference population,
with figures and tables being made to show the results. For gender, the relative risk
calculation utilized the comparison between males and females, with females being the
baseline. For age, the relative risk was compared between age strata with the entire
population as the reference population to assess which age groups had increased risk of
uncontrolled asthma. For socioeconomic status, the SIMD category was used to find the
relative risk between each category with the entire population as the reference population
to see if there were any differences in socioeconomic status contributing to asthma burden.
SIMD is a numerical ranking of socioeconomic status. It separates the population into equal
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categories from 1 to 5, with 1 being the most deprived and 5 being the least deprived. This
means that 1 represents the lowest socioeconomic status, while 5 represents the highest
socioeconomic status. Objective 3 looked at asthma prescribing in 2014 and 2018 and
compared the claims to the SIGN/BTS guidelines to assess changes over time. This looked
at the co-prescribing of SABA and ICS prescriptions and broke it down to percent of >3,
>6, >12 SABAs, Any ICS, and ICS ≥12. SABA and ICS are the main medications used to
treat asthma, and when looking at the SIGN/BTS guidelines, they now represent first-line
treatment (Figure 2, appendix). The treatment guidelines become more complicated after
the first two steps and become more complicated to test. Relative risks were then calculated
to see if there were changes over time in ICS prescribing, utilizing 2014 as the baseline
data. Those receiving SABA and ICS inhalers were further broken down into the percent
receiving ≥12 ICS to assess if there were an adequate number of ICS inhalers prescribed.
This again utilized 2014 as the baseline data for the relative risk calculations. The data
extraction and figures were made with BusinessObjects. The raw data was also exported
into Microsoft Excel where the calculations, including relative risk, were made.
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Results
A total of 222,637 patients received a SABA medication in 2014 and 205,758 patients in
2018. These numbers represent the total study population utilized. Table 1 shows the
patient counts for those receiving SABAs, LABAs, and ICSs.
Table 1 – Patient counts
2014

2018

Total Population aged 0-39

2,545,486

2,592,524

Any SABA (study
population)

222,637

205,758

>3 SABA

97,363

87,227

>6 SABA

48,602

42,732

>12 SABA

19,705

15,263

Any ICS

126,136

122,763

ICS >/= 12

12,579

11,340

ICS >14

5,443

4,541

Any LABA

42,518

44,920

Single-component LABA

3,375

1,345

Any LABA and no ICS

231

171

When looking at the total population aged 0-39 in Scotland for the two years (2,592,524 in
2018 and 2,545,486 in 2014), 7.9% of the population in 2018 and 8.7% of the population
in 2014 received a SABA. Of those receiving a SABA in 2018, 7.42% received >12 SABAs
per year, 20.77% received >6 SABAs per year, and 42.39% received >3 SABAs per year.
In 2014, those numbers were 8.85%, 21.83%, and 43.73% respectively. To show the
differences, the relative risk was calculated and put into a table listing the relative change
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along with the absolute change. The relative risk calculations used 2014 as a baseline, and
therefore it is the reference population. The results of objective 1 are shown in Table 2.
Table 2 – Relative and absolute change between years
2014
>3 SABAs
>6 SABAs
>12 SABAs
Any ICS
ICS >/= 12
>14 ICS
Any LABA
Single

43.73%
21.83%
8.85%
56.66%
5.65%
2.44%
19.09%
1.52%

2018
42.39%
20.77%
7.42%
59.66%
5.51%
2.21%
21.83%
0.65%

Relative Risk (CI)

Relative

Absolute

change

change

0.97 (0.96 – 0.98 P

3.06%

1.43%

<0.001)

decrease

decrease

0.95 (0.94 – 0.96 P

4.87%

1.06%

<0.001)

decrease

decrease

0.84 (0.82 – 0.86 P

16.19%

1.34%

<0.001)

decrease

decrease

1.05 (1.04 – 1.06 P

5.31%

3%

<0.001)

increase

increase

0.97 (0.95 – 0.99 P

2.5%

0.14%

=0.048)

decrease

decrease

0.90 (0.87 – 0.94 P

9.73%

0.23%

<0.001)

decrease

decrease

1.14 (1.13 – 1.16 P

14%

2.74%

<0.001)

increase

increase

0.43 (0.40 – 0.46 P

57%

0.87%

<0.001)

decrease

decrease

0.80 (0.66 – 0.98 P

19%

0.02%

=0.028)

decrease

decrease

component
LABA
Any LABA,

0.10%

0.08%

no ICS

For objective 2, only the year 2018 was examined. Utilizing the amount of SABA
inhalers prescribed to gauge asthma control, SABAs received per year were analyzed in
>12, >6, and >3 inhaler groups and compared between demographics. The rates of these
various SABA quantities were graphed with gender, age strata, and SIMD. On the y-axis
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of the histograms is the rate of those receiving >3, >6, or >12 SABA inhalers out of all
those receiving at least one SABA inhaler per 1000. On the x-axis, it is broken down into
the age bands, gender, and SIMD. The blue bars represent the females, and the green bars
represent the males. The numbers 1-5 represent the SIMD or socioeconomic status, with
1 representing the lowest socioeconomic status and 5 representing the highest
socioeconomic status. The age bands are ordered from left to right of the 0-9, 10-19, 2029, and 30-39 age bands. This gives a broad snapshot of every demographic component
that was measured in objective 2. These are shown in figures 3, 4, and 5.

Figure 3 – Rate of >3 SABA per 1000 stratified by age, SIMD, and gender

17

Figure 4 – Rate of >6 SABA per 1000 stratified by age, SIMD, and gender

Figure 5 – Rate of >12 SABA per 1000 stratified by age, SIMD, and gender
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Age
When looking at the figures, figure 3 shows the rate of >3 SABAs is highest in the age
band 0-9, followed by 30-39. When looking at figure 4, the rate of >6 SABAs the figure
levels off between age strata, but more differences can be seen between gender and SIMD.
Lastly, figure 5, the >12 SABAs figure, shows that the relative risk becomes greater for the
age band 30-39. To illustrate these figures numerically, the relative risk was calculated in
>3, >6, and >12 SABA groups between the age strata. These age results are tabulated and
shown in table 3.
Table 3 – Age relative risk stratified by SABA quantity
0-9
>3 SABAs 1.45 (1.43 – 1.46
P<0.001)
>6 SABAs 1.14 (1.12 – 1.16
P<0.0001)
>12 SABAs 0.99 (0.95 – 1.02
P=0.49)

10-19
0.78 (0.77 – 0.79
P<0.001)
0.70 (0.70 – 0.71
P<0.0001)
0.62 (0.60 – 0.65
P<0.0001)

20-29
0.84 (0.83 – 0.85
P<0.0001)
0.96 (0.94 – 0.98
P<0.001)
1.05 (1.02 – 1.09
P=0.0034)

30-39
1.01 (0.99 – 1.02
P=0.075)
1.21 (1.19 – 1.24
P<0.0001)
1.34 (1.30 – 1.39
P<0.0001)

Gender
When looking at gender, there is an increased relative risk for males when compared to
females. There is a 30% increased risk of receiving >12 SABAs, 25% increased risk for >6
SABAs, and 21% increased risk for >3 SABAs. The results are shown in table 4.
Table 4 – Gender relative risk stratified by SABA quantity
>12 SABAs
>6 SABAs
>3 SABAs

Relative Risk (CI)
1.30 (1.26, 1.34)
1.25 (1.22, 1.27)
1.21 (1.20, 1.22)
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P
<0.001
<0.001
<0.001

SIMD
When looking at SIMD, there is an apparent higher relative risk attributed to the lowest
socioeconomic status groups, and as the socioeconomic status category decreases, the
relative risk increases. This is shown in figures 6, 7, 8.
Figures 6 – SIMD relative risk in >3 SABA group

Figure 7 – SIMD relative risk in >6 SABA inhaler group
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Figure 8 – SIMD relative risk in >12 SABA group

For objective 3, the SIGN/BTS guidelines were used. The co-prescribing of SABA and
ICS represents the optimum treatment, with both a reliever and preventer medication. The
year 2014 and 2018 were compared to see the changes over time. In 2018, 89% of those
receiving >12 SABAs had received an ICS. When looking at the number of ICS inhalers
received in those receiving >12 SABAs and at least 1 ICS, 41% received the recommended
12 ICS inhalers. Table 5 shows the comparison between years in the co-prescribing of
SABA and ICS.
Table 5 – Co-prescribing of SABA and ICS

>3
Any ICS
SABA
Percent ICS ≥12
of those with Any
ICS
>6
Any ICS
SABA

2014

2018

Relative Risk
(CI)

Relative
Change

Absolute
Change

77.02%

78.62%

15.88%

15.48%

1.02 (1.01 – 1.03
P<0.0001)
0.98 (0.95 – 0.99
P=0.0395)

2.07%
increase
2.49%
decrease

1.6%
increase
0.4%
decrease

84.88%

86.09&

1.01 (1.01 – 1.02
P<0.0001)

1.43%
increase

1.21%
increase
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>12
SABA

Percent ICS ≥12
of those with Any
ICS
Any ICS

25.64%

24.86%

0.97 (0.95 – 0.99
P=0.0123)

3.05%
decrease

0.78%
decrease

87.96%

89.08%

Percent ICS ≥12
of those with Any
ICS

41.13%

41.39%

1.01 (1.01 – 1.02
P=0.0011)
1.01 (0.98 – 1.03
P=0.6415)

1.27%
increase
0.64%
increase

1.12%
increase
0.26%
increase
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Discussion

When looking at asthma medication prescribing, one can see that there are a good
number of patients in Scotland that received a SABA medication. While this undoubtedly
over-estimates the number of asthmatics in Scotland, when looking at reported incidences,
comparisons can be made to see how much it overestimates. The incidence of asthma in
Scotland is said to be 1 in 14 that are currently receiving treatment [10]. Utilizing
population counts in the determined age strata showed the study population had an
incidence of 1 in 11 receiving SABA claims in 2014 and 1 in 13 in 2018. This shows that
while it may overestimate the number of asthmatics, it represents a study population that
should encompass the asthma population in the age strata, with additional patients that
utilize SABAs for other ailments.
When comparing the 2014 and 2018 data, it shows the total 0-39 population
increases between the years while the number of patients receiving a SABA medication
decreases. This result is consistent throughout the filter quantity of SABA inhalers. When
looking at relative risk, there is a relative decrease of patients receiving drug claims for
SABAs, and this becomes greater as the filter for the number of SABA inhaler increases.
The most substantial reduction in patient SABA claims occurs in the >12 SABA group.
This reduction shows that there is a relative decrease of 16.19% compared to 2014. When
thinking about the NTI and guideline changes, this is in line with them because there was
an emphasis on patients receiving >12 SABAs after the NRAD data was published. It
appears prescription drug claims for the asthmatics with the least controlled asthma, that
are receiving the most SABAs, have had a greater reduction. This could be due to any one
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of the changes mentioned previously, but the change is significant enough to show positive
changes that have occurred after the NRAD. Although, when looking at the absolute
change, there has been a small change of 1.34% between the years. This small absolute
change likely indicates there is more room for improvement. When looking at the other
measures, there is not as large of a decrease in both relative risk change and absolute risk
change. This may show that the patients receiving the most inhalers are getting the most
attention when it comes to the over-reliance of reliever medications. At the same time, it
appears that there remains room for improvement in the other categories. The amount of
room for improvement in the other categories needs additional review so that more
definitive information with diagnosis codes can help dictate measures. Additionally, this
data shows that there remain 15,263 patients that receive >12 SABAs, a risk for poor
outcomes.
The changes in ICS drug claims between the years shows a decrease in the number
of patients with ICS claims in all three categories. When looking at relative risk, there is a
9.73% decrease in patients receiving >14 ICS. This represents a cost-saving initiative for
the NHS and does not relate to clinical outcomes. When looking at the clinical measures,
there was an increase in the percentage of patients receiving any ICS inhaler. This equated
to a 3% absolute increase (the largest absolute change in objective 1) and a 5.31% relative
increase between the years. ICS inhalers have become more common due to the
preventative nature of their mechanism. In the guidelines, they have become an option for
first-line therapy. These relative and absolute increases coincide with the guideline changes
and could show that more patients are being started on ICS inhalers. If the patient has
asthma, then they have an indication for an ICS inhaler. When considering the amount of
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ICS inhalers, a patient needs, you have to consider the mechanism of action. ICSs are a
medication that a patient needs to take every day. Given that the NHS/BTS formulary has
only ICS inhalers that contain 30-day supplies, one would expect asthmatics to need 12
ICS inhalers per year if they are prescribed them. When looking at the data, there is a 2.5%
relative decrease between years of patients receiving ≥ 12 ICS inhalers compared to 2014.
This statistic alone is hard to analyze, but in objective 3, it looks more into this and assesses
if those with uncontrolled asthma are adequately getting treated with goal-directed therapy.
The big take-away from the ICS component of objective 1 is that those receiving SABA
inhalers in 2018 are receiving ICS inhalers at a higher frequency than in 2014. While the
frequency of those receiving ≥12 has decreased.
LABA inhalers’ place in therapy is more convoluted than SABAs and ICSs. While
SABA and ICS represent first-line therapy options, LABA inhalers represent therapy later
in the sequential stepwise nature of the SIGN/BTS guidelines. Given previous studies’
results on the use of LABA as monotherapy [25], assessing if prescribing has changed is
pertinent to ensuring optimum therapy. While the percentage of patients receiving any
LABA has increased between the years, when breaking it down to single-component and
monotherapy, LABA prescribing has decreased. The single-component LABA statistic
represents something that could have a clinical difference. The NRAD showed that singlecomponent LABA was a risk factor for poorly controlled asthma. If a patient receives a
prescription for a single-component LABA, they may only be using that inhaler regardless
of other inhalers that have been prescribed to them. This increases the chance that an
asthmatic is using LABA as monotherapy. Instead, NRAD and guidelines have moved
towards prescribing LABAs that are included in combo inhalers [12]. That is LABA and
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ICS in one inhaler. Combo inhalers can increase compliance to goal-directed medical
therapy and decrease the chances that a patient uses LABA as monotherapy. Looking at
the changes in monotherapy or single-component LABAs shows the greatest relative
decrease in all medication categories. There was a 57% relative decrease in patients
prescribed single-component LABAs between the years, a 19% relative decrease in any
LABA without an ICS, and a 47% relative decrease in single-component LABA without
an ICS. This represents a decrease in the prescribing of LABAs and a potential decrease in
those at-risk for poor outcomes that coincide with LABA monotherapy.
For objective 2, the year 2018 was used to assess demographic and socioeconomic
status differences. SABA inhaler claims were the only medication examined and again
under the assumption that the more inhaler claims, the less the asthma is controlled. When
looking at the figures of the number of SABA inhalers with age strata, gender, and
socioeconomic status, it gives a good insight into how prescribing differs between these
various groups. The y-axis of figures 3, 4, and 5 show the rate of SABA inhalers per 1000
patients. While the scale changes in each of the three figures, making it harder to compare,
the rate in the various groups in the individual figures can be compared. In figure 3, the
age band 0-9 has the highest rate of >3 SABAs, and there is not an easily visible difference
between socioeconomic status among this age band. Then when looking at figure 4 (>6
SABAs), the rate between age strata starts to level off. The differences between gender and
socioeconomic status become more pronounced in this figure, as well. Figure 5 has the
most noticeable differences between socioeconomic status and gender. Also worth noting
is that the age band 30-39 now has the highest rate of those receiving >12 SABAs when
compared to the other age strata.
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As discussed previously, the 0-9 age band has the highest rate in >3 SABAs with
45% increased relative risk of getting >3 SABAs compared to the other age strata. As the
number of inhalers increases to the >6 SABAs and >12 SABAs groups, the relative risk
decreases for the 0-9 age band. While in the age band 30-39, the relative risk increases as
the number of SABA inhalers increases. In the >12 SABAs group, there is a 34% increased
relative risk in the 30-39 group compared to the other age strata. These increases in rate in
the oldest population group as the number of SABA inhalers increase may be due to
behavioral health factors. This observation would coincide with previous data on smoking
and asthma, showing that smoking increases the risk of asthma and asthma that is more
difficult to control [26]. The takeaway from this portion of the data is that younger age
individuals may be at greater risk of needing a SABA, but as age increases, so does the
apparent rates of uncontrolled asthma and the need for large quantities of SABA inhalers.
When trying to understand and treat asthma for those in adulthood, these results should be
taken into consideration, and behavioral health factors must be assessed. Being able to
identify behavioral health factors like smoking or environmental exposures can help to aid
in the treatment of asthma.
When looking at gender, there is a clear and definitive takeaway. Males are at an
increased risk of needing SABA inhalers, and that risk increases as the number of SABA
inhaler increases. The difference between the two genders is significant, with a 21%
relative increase in >3 SABAs, a 25% relative increase in >6 SABAs, and a 30% relative
increase in >12 SABAs. Males appear to be at an increased risk of asthma in this
population, and the data shows they are also at an increased risk of needing SABA inhalers.
The last component of objective 2 is the socioeconomic status. As discussed
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previously, SIMD is the NHS breakdown of socioeconomic status. SIMD 1 represents the
most deprived or the lowest socioeconomic status, and SIMD 5 represents the least
deprived of the highest socioeconomic status. To make the results more evident, the relative
risks and 95% confidence intervals were graphed as a forest plot. One can see that there is
a linear difference in relative risk; going from the highest SES to the lowest SES, the
relative risk for SABA inhalers increases. When comparing the three figures, one can see
that as the number of inhalers increase, so does the spread between the groups. In the >12
SABA figure, the most significant spread between relative risk in the SIMD groups. Those
in the lower SIMD groups were assumed to have the least controlled asthma, and the
graphs/data support this assumption. This represents some information that can help
identify those at the highest risk, so that catered, and individually focused plans can be
initiated by providers to try and lessen the burden that coincides with SES. When thinking
about reasons for these discrepancies, environmental exposures, and behavioral health
factors such as smoking emerge as potential culprits. Understanding likely socioeconomic
differences can help healthcare and public health workers to more easily identify those at
risk so that campaigns can be developed to limit the differences in exposure while also
allowing tighter monitoring with medical therapy. Practitioners in Scotland should be alert
to risk factors that their patients may have in relation to their SES.
For objective 3, changes in the SIGN/BTS guidelines were investigated, and data
was analyzed to ascertain how they may have changed prescribing habits. The two firstline therapy medications of SABA and ICS were investigated. The significant changes in
the guidelines have been the increasing priority of adding on ICSs and adding them to firstline therapy options. Previously ICS were down the stepwise guidelines path, reserved for
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those not controlled by SABAs. It is assumed that as the number of SABA inhaler claims
increases, so too will the need for ICS. If patients do not have controlled asthma, then they
should be on an ICS. When thinking about how ICS medications work, if a patient is on an
ICS medication, they should receive one inhaler every month. This means that in a calendar
year, they should have 12 claims for ICS medications. As the number of SABA
medications increase, it is hypothesized that asthma is less controlled. So those receiving
>12 SABAs should have ICS claims, and they should have ≥12 ICS claims. The ICS and
SABA co-prescribing data were compared between the years to see how the guidelines
might have influenced prescribing. When looking at the data, prescribing of ICSs has
changed little. In the >3 SABA group, the prescribing of any ICS occurred in 77% in 2014
and increased to 79% in 2018, a relative risk increase of 2.07%. In this group, there was a
decrease in those receiving ≥12 ICS inhalers from 15.88% to 15.48%. In the >6 SABA
group, there was an increase in those having any ICS claims from 84.88% to 86.09%. There
was also a decrease in those receiving ≥12 ICS medications, moving from 25.64% to
24.86%. In the last group, those receiving >12 SABAs, there was an increase in those
receiving any ICS from 87.96% to 89.08%. This change resulted in only a 1.27% relative
risk increase between the years. This group was the only group that had an increase in those
receiving ≥12 ICS inhalers. But this was only a 0.64% relative increase between the years.
It is more difficult to take away much information from the >3 or >6 SABAs groups due
to the uncertainty of determining asthma control and uncertainty of the timing of the paid
claims in the year. But when looking at the >12 SABA group, it is a bit easier to make
assumptions about asthma control. In those receiving >12 SABAs, it is a clear indication
for an ICS medication. One would expect that if they need that many reliever medications
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that they would get at least one preventer medication. While this number has increased, it
still is not at 100%. There remains 11% of the population that receives >12 SABAs that do
not have adequate therapy based upon the SIGN/BTS guidelines. This equates to 1,667
patients that are not receiving adequate goal-directed medical therapy and are therefore atrisk for poor outcomes. For those receiving >12 SABAs and having claims for an ICS, the
rates of those receiving ≥12 ICSs are lower than anticipated. Only 41.39% had received
≥12 ICSs in 2018; a number only slightly increased from 2014 at 41.13%. This results in
7,968 patients that are not receiving an adequate number of ICS inhalers per year. This
number could represent poor compliance with ICS medications for those receiving >12
SABAs. It is clear that ICS medications have numerous side effects [27]; this represents a
potential reason for patients to stop taking them. If this does accurately represent a picture
of poor compliance for ICS medications, then this is a clear area where healthcare providers
and public health workers can make a difference. Poor adherence presents an opportunity
to develop campaigns aimed at either the patients with asthma or the providers to address
concerns of ICSs directly. These campaigns could ultimately allow higher compliance and
better outcomes. If this is an issue with prescribing, then awareness campaigns can be
created to target prescribers and the areas with poor co-prescribing.
Limitations
Limitations of this study include the lack of diagnosis codes. Without the diagnosis
codes, the population had to be assumed to have asthma. This assumption overestimated
those with asthma. It also forced the creation of age strata in which populations at-risk may
have been suppressed. The age groups 40 and greater could represent additional data that
could help show how guideline changes, studies, and NTI influenced prescribing. Data
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analysis was limited to relative risk. Other statistical tests could be used with this data, and
alternative study design could be made to give more definitive results and show new
results. This data does not consider adherence. Without adherence, assumptions must be
made about prescribing. If it turns out adherence is an issue, then the focus could shift to
addressing poor adherence as opposed to influencing prescribing. The last perceived
limitation is the lack of outcome measures, including hospitalization records or cost-saving
measures. Hospitalizations represent a clinical and cost measure. Seeing the demographics
of those needing hospitalization for asthma could either bolster data from this study, or it
could bring additional information about who is at-risk for poor outcomes.
Implications
This study shows how asthma prescribing has changed over the years. It highlights
areas were good progress has been made and shows areas where there remains room for
improvement. Since the NRAD, there have been changes to try and influence outcomes.
Seeing the data change and looking in-depth in the most recent full year of data gives an
understanding of how these changes have influenced outcomes. It appears that more
considerable attention has been focused on those with a higher risk of poor outcomes. More
studies will be needed to investigate those below the far extreme category of this study.
Still, there remain 15,263 patients at risk for poor outcomes due to excessive SABA use,
1,667 patients not on goal-directed medical therapy with ICS medications, and 7,968
patients were not receiving adequate amounts of ICS inhalers. This highlights areas that
are still in need of improvement. When looking at the demographical analysis, this
represents excellent insight to those at-risk for poor outcomes. The demographical analysis
can be used to initiate more studies in these demographics to confirm the results and
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investigate reasons for the differences. It can also be used as a marker for patients that may
be at higher risk so that public health officials and practitioners can implement strategies
to curtail any burden associated with these demographics.
The resources NHS Scotland have at their disposal and ability to analyze their full
population allow better monitoring and implementation of public health measures. Data
replicated on patients in the United States may not be able to encompass the entire
demographics, environmental differences, and regional differences that coincide with the
United States. But this study can highlight how the implementation of guidelines and public
health measures like the NTI, can change prescribing habits. NTIs could ultimately be
replicated in the United States to more easily compare data throughout the country. Another
advantage of the publicly funded healthcare system is that there is no cost for prescriptions
to the patients. This likely eliminates an area for medical access issues and removes a
potential confounder for outcomes that can be apparent in the United States. This likely
means more patients are on the medications that were prescribed to them. While this does
not guarantee a patient takes the medications as prescribed to them, it likely means fewer
hurdles for the patients and more compliance. Thus, more can be concluded about the
changes in prescribing habits and how guidelines, public health initiatives, and research
can influence prescribing habits.
Conclusion
There appears to be an over-reliance on reliever medications, with a deficit in
preventer medication use. This finding has improved from previous years’ data but
highlights areas with room for improvement. Certain groups of the Scotland population are

32

at increased risk for large numbers of SABA inhalers – males, low socioeconomic status,
and the age band 30-39. Lastly, based on NRAD findings, there seems to remain a large
population at risk for poor outcomes.
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Appendix
Figure 1 – 2014 SIGN/BTS asthma guidelines

Source: [28]
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Figure 2 – 2016 SIGN/BTS asthma guidelines

Source: [29]

39

